Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
20.78
-0.67 (-3.12%)
Oct 30, 2026, 11:32 AM EDT - Market open
Cue Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 37.66 | 27.47 | 9.29 | 5.49 | 1.25 | 14.94 | |
Revenue Growth | 354.44% | 195.75% | 69.16% | 340.96% | -91.67% | 373.68% |
Cost of Revenue | 74.99 | 34.84 | 32.9 | 40.8 | 35.3 | 41.35 |
Gross Profit | -37.34 | -7.38 | -23.61 | -35.31 | -34.05 | -26.41 |
Selling, General & Admin | 61.31 | 19.14 | 17.99 | 16.68 | 19.45 | 17.31 |
Operating Expenses | 61.31 | 19.14 | 17.99 | 16.68 | 19.45 | 17.31 |
Operating Income | -98.64 | -26.52 | -41.59 | -51.99 | -53.5 | -43.71 |
Interest Expense | -0.19 | -0.36 | -0.8 | -1.25 | -0.71 | - |
Interest & Investment Income | 0.78 | 0.81 | 1.62 | 2.66 | 0.93 | 0.05 |
Other Non Operating Income (Expenses) | -65.52 | - | - | - | - | - |
EBT Excluding Unusual Items | -163.59 | -26.07 | -40.77 | -50.58 | -53.29 | -43.67 |
Gain (Loss) on Sale of Assets | -0.03 | -0.03 | 0.09 | -0.16 | 0.28 | - |
Pretax Income | -163.61 | -26.1 | -40.67 | -50.73 | -53.01 | -43.67 |
Income Tax Expense | 0.5 | 0.5 | - | - | - | 0.5 |
Net Income | -164.11 | -26.6 | -40.67 | -50.73 | -53.01 | -44.16 |
Net Income to Common | -164.11 | -26.6 | -40.67 | -50.73 | -53.01 | -44.16 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 5 | 3 | 2 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 5 | 3 | 2 | 2 | 1 | 1 |
Shares Change | 84.06% | 68.18% | 23.11% | 28.35% | 13.95% | 9.05% |
EPS (Basic) | -36.22 | -8.42 | -21.66 | -33.26 | -44.61 | -42.35 |
EPS (Diluted) | -36.22 | -8.42 | -21.66 | -33.26 | -44.61 | -42.35 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -50.17 | -21.86 | -36.4 | -39.96 | -41.98 | -39.75 |
Free Cash Flow Per Share | -11.07 | -6.92 | -19.38 | -26.20 | -35.33 | -38.12 |
Gross Margin | -99.15% | -26.86% | -254.21% | - | - | -176.73% |
Operating Margin | -261.97% | -96.56% | -447.86% | -947.03% | -4297.35% | -292.56% |
Profit Margin | -435.82% | -96.85% | -437.97% | -924.10% | -4257.83% | -295.56% |
Free Cash Flow Margin | -133.23% | -79.60% | -391.89% | -727.89% | -3371.65% | -266.04% |
EBITDA | -97.28 | -25.56 | -41.2 | -51.44 | -52.58 | -42.45 |
EBITDA Margin | -258.36% | -93.07% | - | - | - | -284.14% |
D&A For EBITDA | 1.36 | 0.96 | 0.4 | 0.56 | 0.92 | 1.26 |
EBIT | -98.64 | -26.52 | -41.59 | -51.99 | -53.5 | -43.71 |
EBIT Margin | -261.97% | -96.56% | - | - | - | -292.56% |